Atherosclerosis is an arterial disease process characterized by the focal subendothelial accumulation of apolipoprotein-B-containing lipoproteins, immune and vascular wall cells, and extracellular matrix. The lipoproteins acquire features of damage-associated molecular patterns and trigger first an innate immune response, dominated by monocyte-macrophages, and then an adaptive immune response. These inflammatory responses often become chronic and non-resolving and can lead to arterial damage and thrombosisinduced organ infarction. The innate immune response is regulated at various stages, from hematopoiesis to monocyte changes and macrophage activation. The adaptive immune response is regulated primarily by mechanisms that affect the balance between regulatory and effector T cells. Mechanisms related to cellular cholesterol, phenotypic plasticity, metabolism, and aging play key roles in affecting these responses. Herein, we review select topics that shed light on these processes and suggest new treatment strategies.
A Brief Overview of Atherogenesis and Atherosclerotic Plaque Progression
Atherogenesis is initiated by the entry and retention of apolipoprotein-B-containing lipoproteins (apoB LPs) into the subendothelial space, or ''intima,'' at regions of disturbed blood flow in medium-sized arteries (Williams and Tabas, 1995; Fogelstrand and Boré n, 2012) . The amount of apoB LP retention is determined by the concentration of apoB LPs in the blood, the age and metabolic state of the individual, and genetic and environmental factors. These considerations affect arterial wall biology, including variations in subendothelial proteoglycans that retain apoB LPs and factors that alter endothelial permeability. Initially, some of the lipoprotein lipid is internalized by resident CD11c + myeloid cells, and experimental depletion of these cells suppresses the early accumulation of foam cells and intracellular lipids (Paulson et al., 2010) . Then, certain lipid and protein components of subendothelial apoB LPs, particularly after oxidative modification, take on properties of damage-associated molecular patterns (DAMPs) and thereby trigger an inflammatory response (Glass and Witztum, 2001; Lusis, 2000) . This response activates endothelial cells and, together with flow-mediated changes in these cells (Jongstra-Bilen et al., 2006; Gimbrone and García-Cardeñ a, 2013) , promotes the entry into the intima of bone-marrow-derived monocytes (Tacke et al., 2007; Swirski et al., 2016) . The Ly6C hi subpopulation of monocytes in the intima differentiates into macrophages, which, in progressing lesions, take on an inflammatory phenotype (Tacke et al., 2007; Swirski et al., 2007) . In part as a result of the accumulation of inflammatory macrophages and dendritic cell (DC) activation, an inflammatory adaptive immune response involving primarily T helper 1 (Th1) cells, but also Th17 and Th2 cells and B cells, develops in conjunction with a progressive decrease in regulatory T (Treg) cells (Witztum and Lichtman, 2014) . Other immune cells, including neutrophils and platelet-neutrophil aggregates, innate immune cells, natural killer cells, mast cells, and eosinophils, are present in human atheroma and have been shown to promote atherosclerosis via additional mechanisms in mouse models (Witztum and Lichtman, 2014) . Accompanying this immune cell reaction is the accumulation of myofibroblasts in the intima; these arise from medial smooth muscle cells and other sources and are referred to as vascular smooth muscle cells (VSMCs) (Bennett et al., 2016) . These cells are rich sources of extracellular matrix, which most likely represents a ''scar'' response to inflammation and the ongoing vascular injury. In a physiologic post-inflammatory response, macrophages and other inflammatory cells secrete molecules and carry out functions that dampen the inflammatory response and promote tissue repair (Serhan et al., 2007; Nathan and Ding, 2010) . However, as will be explained later in this review, this so-called resolution response can go awry in the setting of atherosclerosis. Impaired resolution in atherosclerotic lesions leads to sustained, non-resolving, and maladaptive inflammation that promotes plaque progression and, in humans, triggers acute thrombo-occlusive cardiovascular events (Merched et al., 2008; Tabas, 2010; Viola and Soehnlein, 2015) . The pathological features of clinically dangerous plaques include large areas of necrosis and thinning of an overlying collagenous, or fibrous, cap. When a breach forms in the fibrous cap, blood is exposed to thrombogenic material in the lesion, and acute occlusive thrombosis with tissue infarction can ensue (Virmani et al., 2002; Libby, 2013) . However, acute thrombotic vascular events can also occur in the vicinity of more fibrous, non-necrotic plaques that are characterized by endothelial erosion (Libby, 2017) . Studies in mice have suggested that this latter process is promoted by flow disturbance and neutrophilmediated effects on endothelial cells (Franck et al., 2017) .
In the sections that follow, we will review a selective subset of innate and adaptive immune processes that have recently come to light as affecting atherogenesis and/or plaque progression. The reader is referred to the reviews cited above and original references cited in these reviews for the many important immune processes in atherosclerosis that are not included herein. subpopulation in mice, is strongly correlated with atherosclerotic vascular disease in humans and the development of atherosclerotic lesions in mice (Olivares et al., 1993; Murphy and Tall, 2016) . In this context, recent studies have provided fascinating new insight into the regulatory mechanisms of monocytosis relevant to atherosclerosis (Figure 1 ). The role of the sympathetic nervous system (SNS) came to light as researchers sought to explain why atherosclerosis accelerates after myocardial infarction (MI). In the setting of an inflammatory response, Ly6C hi monocytes initially give rise to macrophages on the inflammatory end of the inflammatory-resolution spectrum, and as will be discussed in the following paragraphs, these macrophages promote atherosclerosis progression (Swirski et al., 2007) . A substantial portion of Ly6C hi monocytes that contribute to atherosclerosis originate from the spleen, which becomes populated with bone-marrow-derived hematopoietic stem and progenitor cells (HSPCs) and carries out extramedullary hematopoiesis . In this context, mouse studies suggest that a key mechanism of post-MI atherosclerosis is SNS-mediated release of HSPCs from the bone marrow, which leads to seeding of the spleen, elevated extramedullary hematopoiesis, and increased release of Ly6C hi monocytes, which drive atherogenesis (Dutta et al., 2012) . Further evidence suggests that other stress-related events that are known to be risk factors for atherosclerotic disease, such as psychosocial stress, might work through a similar mechanism (Heidt et al., 2014) . How these concepts apply to human atherothrombotic vascular disease remains an important area for future study, particularly in view of uncertainties related to the functions of CD14 ++ monocytes in humans (Hilgendorf and Swirski, 2012) .
Hypercholesterolemia also promotes monocytosis, particularly Ly6C hi monocytosis, in mice (Swirski et al., 2007) , and defective cholesterol efflux in HSPCs effected by genetic targeting of cholesterol efflux proteins can also exacerbate Ly6C hi monocytosis (Murphy and Tall, 2016) (Figure 2 ). The mechanism responsible for cholesterol-induced monocytosis involves expansion of Lin À cKit + Sca1 + HSPCs in the marrow compartment (Murphy and Tall, 2016) . Mechanistic studies revealed that cholesterolmediated changes in the plasma membrane of HSPCs lead to elevated cell-surface expression of the common b-subunit of the interleukin-3 (IL-3) and granulocyte-monocyte colony-stimulating factor (GM-CSF) receptors and increased sensing of two Lesional macrophages originate from bone-marrow-derived hematopoietic stem and progenitor cells (HSPCs), which give rise to circulating monocytes. In certain instances, these stem cells first populate the spleen and then undergo extramedullary hematopoiesis. Proliferation and release of HSPCs can be exacerbated by elevated cellular cholesterol and by somatic mutations leading to clonal hematopoiesis, such as those that occur in aging and myeloproliferative disease (MPD). This process can also be stimulated by stress-induced activation of the sympathetic nervous system (SNS). The major subpopulation of monocytes that contribute to atherosclerosis progression are Ly6c hi monocytes, which enter lesions in response to subendothelially retained apolipoprotein-B-containing lipoproteins (LPs) and subsequent chemokine release by activated endothelial cells. After differentiation into macrophages, these myeloid cells undergo a variety of phenotypic changes under the influence of the factors listed in the figure. Those macrophages on the inflammatory end of the spectrum secrete proteins and carry out processes that promote atherosclerosis progression, whereas those on the resolution end of the spectrum promote lesion regression.
key HSPC growth factors, IL-3 and GM-CSF (Yvan-Charvet et al., 2010) . There is also evidence that hypercholesterolemia, presumably by increasing the cellular content of cholesterol, decreases the expression of Rb, a tumor suppressor that limits HSPC proliferation, and increases the expression of cyclins B1, D1, and E1 in HSPCs . Interestingly, when normocholesterolemic recipient mice were transplanted with bone marrow from either normocholesterolemic or hypercholesterolemic donor mice, the HSPCs of hypercholesterolemic donor origin showed increased proliferation 10 weeks later . These data suggest a long-lived, cell-intrinsic effect of hypercholesterolemia on HSPCs, perhaps as a result of epigenetic changes in the donor HSPCs. Moreover, when Ldlr À/À mice were transplanted with bone marrow cells from hypercholesterolemic or normocholesterolemic mice and then fed a Western-type diet rich in cholesterol and saturated fats, the mice that had received that hypercholesterolemic bone marrow developed larger and more advanced lesions. This increase in atherosclerosis was accompanied by a higher number of lesional leukocytes derived from the hypercholesterolemic mouse bone marrow cells and overall increases in plaque macrophages, granulocytes, and T cells. Other recent studies have taken advantage of the fact that leukocytosis in myeloproliferative disease (MPD) is associated with atherothrombotic vascular disease (Murphy and Tall, 2016 (Viny and Levine, 2014) . Although processes related to neutrophils and platelets most likely contribute to the mechanism of this association, there is also a link to monocytosis. In this context, genetic targeting of Lnk in Lnk
Western diet has been found to cause hypercholesterolemiadependent monocytosis, which is associated with increased amounts of the pro-atherogenic chemokine monocyte chemotactic protein-1 (MCP-1; also known as CCL2) . Most importantly, these mice demonstrate increases in atherosclerotic lesion area, lesional macrophages, Ly6C hi monocyte entry into lesions, and atherogenic platelet-monocyte aggregates . Synergy between hypercholesterolemia and LNK deficiency leads to further increases in IL-3-GM-CSF receptor signaling in bone marrow HSPCs. Further insight into some of these processes emerges from a study showing that Glut1-mediated glucose uptake by inflammatory myeloid cells promotes myeloproliferation in mice with either defective cholesterol efflux or myeloproliferative disorders (Gautier et al., 2013) . In view of the link between glycolysis and inflammatory myeloid cell function (Van den Bossche et al., 2017) , the authors propose that Glut1-mediated glucose uptake provides the energy necessary for inflammatory myeloid cell proliferation. Ly6C lo monocytes derive from Ly6C hi monocytes and serve an endothelial maintenance ''patrolling'' function in the circulation, but their roles in tissues have become increasingly unclear, and it is not even certain whether they differentiate into macrophages (Jakubzick et al., 2017) . As such, the role of Ly6C lo monocytes in In the setting of hypercholesterolemia or defects in cholesterol efflux, HSPCs accumulate excess cholesterol. The consequence is enhanced IL-3 and GM-CSF growth factor signaling, leading to HSPC proliferation and monocytosis. With aging, clonal hematopoiesis can occur as a result of loss-of-function mutations in a number of genes, including TET2. This process might also contribute to monocytosis. Monocytosis is associated with increased accumulation of inflammatory monocyte-derived macrophages in atherosclerotic lesions and a higher risk of atherosclerotic vascular disease in humans. These lesional macrophages are also subject to intracellular cholesterol accumulation because of their internalization of subendothelial apoB LPs. Excess cholesterol in macrophages has multiple effects that enhance lesion inflammation, including activation of toll-like receptors (TLRs) and inflammasomes. The result is increased production of inflammatory chemokines and cytokines, including inflammasome-derived IL-1b and IL-1b-induced IL-6. Moreover, changes associated with clonal hematopoiesis, e.g., loss of TET2 function, can also activate the inflammasome in macrophages, further fueling lesional inflammation. T cells do not have the capacity to accumulate large amounts of excess cholesterol, but several studies have shown that perturbations of T cell cholesterol metabolism can affect T cell differentiation and activation. Impaired ABCG1 cholesterol efflux from T cells results in enhanced Treg differentiation, which reduces atherosclerotic lesion development and inflammation. In contrast, impaired esterification of cholesterol by deficiency or inhibition of acyl-coenzyme A:cholesterol acyltransferase increases the formation of lipid rafts in CD8 + effector T cells and thereby enhances immune synapse formation and killing functions of these cells. The net effect of increases in T cell cholesterol on lesion development and inflammation are likely to reflect changes in the Teff-Treg balance and the influence of Teff cells on lesional macrophages. atherosclerosis is poorly understood. In one study, investigators tested the effect of targeting the nuclear receptor Nr4a1 (Nur77), which is required for the differentiation and survival of Ly6C lo monocytes (Hanna et al., 2011) . Two models of mouse atherosclerosis with genetic targeting of Nr4a1-Western-dietfed Ldlr À/À mice lacking hematopoietic Nr4a1 and Apoe À/À mice with germline targeting of Nr4a1-demonstrated increased atherosclerosis, and this was associated with an increase in the proportion of lesional macrophages that had an inflammatory or a resolving phenotype (Hanna et al., 2011) . Although one interpretation of this finding is that Ly6C lo monocytes directly give rise to resolving macrophages that regulate the inflammatory response, another possible interpretation is that Nr4a1 is required for the conversion of Ly6C hi monocytes into resolving macrophages (Hilgendorf et al., 2014) . For example, Ly6C hi monocytes infiltrate the heart immediately after MI and then, during the repair phase, give rise to Ly6C lo macrophages with resolving properties. However, in mice lacking hematopoietic Nr4a1, infiltrating Ly6C hi monocytes differentiate into highly inflammatory macrophages that are unable to carry out tissue repair. If applicable to atherosclerosis, the data from the Nr4a1-deficient mouse study above could suggest that Ly6 hi monocytes give rise to reparative macrophages in atherosclerotic lesions in an Nr4a1-dependent manner. Consistent with this idea, a recent study showed that Ly6C hi monocytes are the source of resolving macrophages during atherosclerotic plaque regression (Rahman et al., 2017) .
Inflammatory Macrophages Drive Atherosclerosis Progression
Macrophage functions can vary widely depending on a number of interacting variables and factors, including local environment (''tissue niche'') (Gosselin et al., 2014; Lavin et al., 2014) , intracellular energy metabolism (Van den Bossche et al., 2017), gut microbiota metabolites (Wang et al., 2011) , and genetic and epigenetic factors, including non-coding RNAs (Erbilgin et al., 2013; Chen et al., 2015; Wu et al., 2016; Amit et al., 2016; Phan et al., 2017; Aryal et al., 2014) . These factors program macrophages for functions on a spectrum from inflammatory and host defense to resolution and repair. In general, inflammatory macrophages carry out processes that promote atherosclerosis progression, whereas resolving macrophages carry out functions that can suppress plaque progression and promote plaque regression (Peled and Fisher, 2014) (Figure 1 ). By secreting cytokines, proteases, and other factors, inflammatory macrophages increase the cellular expansion of lesions and cause plaque morphological changes that can trigger plaque rupture and acute lumenal thrombosis. Two key changes promoted by inflammatory macrophages are plaque necrosis and thinning of a protective collagenous scar (fibrous cap). Conversely, resolving macrophages carry out functions that are associated with plaque stabilization. These functions include clearing dead cells (efferocytosis), which stabilize plaques by preventing post-apoptotic cellular necrosis; secreting collagen that can form a protective scar over the lesion; and producing proteins and lipids that quell inflammation and promote tissue repair. Molecular profiling of lesional macrophages at various stages of lesion progression and regression has demonstrated heterogeneity suggestive of these different functions (Peled and Fisher, 2014) . One such study using immunohistochemistry and RNA profiling showed that CD68 + macrophages at both ends of the inflammation-resolution spectrum accumulate as atherosclerotic lesions develop (Stö ger et al., 2012) . The relative proportion of macrophages with different phenotypic markers varies depending on plaque region. For example, macrophages on the inflammatory end of the spectrum are enriched in plaque regions that are prone to rupture. In this regard, inflammatory macrophages can secrete matrix metalloproteinases, e.g., MMP2 and MMP9, which might contribute to plaque rupture, and MMPs have been shown to co-localize with inflammatory macrophages in advanced plaques (Huang et al., 2012) . Conversely, plaques that appear more stable based on the presence of thicker fibrous caps and smaller areas of plaque necrosis are found to be enriched in macrophages toward the resolution end of the spectrum, a finding consistent with the aforementioned plaque-stabilizing functions of resolving macrophages. In a similar vein, regressing plaques, which can be modeled in mouse atherosclerosis through the abrupt and marked lowering of plasma cholesterol, show a shift toward the resolution phenotype (Trogan et al., 2006) . Important gaps remain in our understanding of the mechanisms leading to macrophage heterogeneity in various stages of atherosclerosis progression and regression and at different sites within the plaques themselves. A key question is the relative contribution of changes in the types of infiltrating monocytes and changes in pre-existing lesional monocytes or macrophages, such as by proliferation of inflammatory macrophages and phenotypic switching. Macrophage proliferation occurs in atherosclerosis, particularly in advanced plaques (Sakai et al., 2000; Robbins et al., 2013) , but the mechanisms and consequences of lesional macrophage proliferation remain largely unknown. In one study, investigators studied the effect of heterozygous deficiency of Zfp148, which encodes a zinc-finger protein that suppresses the checkpoint protein P53, in hematopoietic cells in atheroprone Apoe À/À mice (Sayin et al., 2014) .
These mice demonstrated a decrease in lesional macrophage proliferation in association with decreases in markers of inflammation and overall lesion area in a P53-dependent manner. Several mechanisms driving macrophage proliferation in atherosclerosis have been proposed, including activation of scavenger receptor class A signaling, activation of the GTPase Ras, and loss of function of the cyclin-dependent kinase inhibitor 2A (CDKN2A), which encodes two cell-cycle inhibitors and is linked to a susceptibility locus for atherothrombotic disease in humans (Sakai et al., 1996; Senokuchi et al., 2005; Kuo et al., 2011) . Regarding the Ras hypothesis, a recent study showed that delivery of an HMG-CoA reductase inhibitor (statin), which blocks Ras activation, to lesional macrophages decreased lesional macrophage proliferation and plaque inflammation (Tang et al., 2015) . Much of the effort in understanding phenotypic modulation of lesional macrophages has focused on environmental cues in lesions that can affect macrophage phenotype. For example, accumulation of cholesterol in these cells can trigger inflammatory signaling pathways, presumably by affecting the plasma membrane in a way that activates inflammatory receptors, e.g. toll-like receptors (TLRs) (Westerterp et al., 2014) (Figure 2 ). Important new work has suggested that this cholesterol-dependent process in macrophages can be exacerbated in the setting of diabetes by increased incorporation of endogenously synthesized fatty acids into cholesterol-rich domains of the plasma membrane (Wei et al., 2016) . Moreover, cholesterol accumulation in macrophages activates the inflammasome, leading to increased production of pro-atherogenic interleukin-1b. Although cholesterol crystals have been implicated in this process (Duewell et al., 2010; Sheedy et al., 2013) , other mechanisms are likely to contribute as well (Hoseini et al., 2017) .
Some of the work in this area has been linked to epigenetic changes at early stages of monocyte-to-macrophage differentiation. For example, exposure of monocytes to oxidized low-density lipoprotein (LDL), a modified LDL form that accumulates in atherosclerotic plaques, ''primed'' the cells for a subsequent increase in their inflammatory response to TLR2 and TLR4 activators (Bekkering et al., 2014) . This response was associated with an epigenetic histone mark of active transcription (trimethylation of H3K4) in the promoters of several of the upregulated inflammatory genes, and the priming response was blocked by a methyltransferase inhibitor. A similar finding was observed during a study that compared monocytes from subjects with symptomatic or asymptomatic carotid atherosclerosis (Bekkering et al., 2016) . Another study showed that HDAC3 inhibitors increased the expression of ABCA1 and ABCG1 in cultured macrophages and that myeloid deletion of HDAC3 in Ldlr À/À mice fed a Western diet suppressed atherosclerosis and promoted a more resolving phenotype in lesional macrophages . The inhibitors used in these studies cause broad changes in histone marks throughout the genome, and thus future studies will be needed to define specific epigenetic changes that contribute to proatherogenic responses in lesional macrophages.
An Increase in the Ratio of Effector T Cells to Treg Cells Promotes Atherosclerosis
As discussed above for macrophages, T cell functional phenotypes can change in response to environmental clues, thereby altering their relative ability to function as regulatory or inflammatory cells. The concept that Treg cells can respond to inflammatory mediators in local tissue environments and take on some of the phenotypic properties of effector T (Teff) cells in those sites is well established. In some cases, Teff-like Treg cells retain their suppressive functions, but in other cases such as autoimmune disease models, Treg cells assume the inflammatory and pathogenic roles of their Teff cell cousins (Sawant and Vignali, 2014) . Treg cells, but not Teff cells, decrease during atherosclerotic lesion development (Maganto-García et al., 2011) , and this could be attributed to phenotypic plasticity, as well as differences between Treg and Teff cells in migration into lesions or susceptibility to death (Figure 3 ). FoxP3 and T-bet are the lineage-defining identified in that study were derived from plastic conventional Treg cells remains unknown. However, because they were found only in the aorta and peri-aortic lymph nodes and not in the spleen, it is possible that they were derived from plaque Treg cells in response to factors in the lesional environment. Interestingly, studies in other lineage-specific T-bet-deletion and FOXP3-reporter models without hypercholesterolemia or atherosclerosis have demonstrated that T-bet-expressing Treg cells are immunosuppressive and required for preventing autoimmunity Yu et al., 2015) . This apparent contradiction in the observed functions of T-bet-expressing Treg cells could indicate that the development of IFN-g-expressing inflammatory T-bet + Treg cells is linked to the unique conditions of systemic hypercholesterolemia and/or the plaque microenvironment. Many studies of Th cell subsets in human autoimmune conditions and mouse models of these diseases reinforce the concept that Teff cells are plastic and can differentiate within inflamed tissues toward more pathogenic phenotypes during disease progression. For example, under the influence of innate inflammatory cytokines, Th17 cells can be changed from barrier-protective Teff cells that secrete IL-17A and IL-10 into pathogenic effectors that secrete IL-17A, IL-22, and IFN-g (Burkett et al., 2015) . This Th17 cell conversion into pathogenic effector cells is promoted by IL-1, IL-6, and IL-23, all of which are known to be expressed in atherosclerotic lesions. The contribution of IL-17 or Th17 cells to atherosclerotic lesion development remains uncertain on the basis of mouse studies, but dual IL-17-and IFNg-producing T cells are present in atherosclerotic human coronary arteries at a higher frequency than in the blood (Eid et al., 2009) . Expression of the IL-23 receptor on Th17 cells plays a non-redundant role in their pathogenic conversion, and Notch signaling via the DNA binding protein RBPJ is required for induction of IL-23R expression by Th17 cells (Meyer Zu Horste et al., 2016). In this context, a recent report has shown that abrogation of RBPJ-dependent Notch signaling reduces atherosclerosis in Apoe À/À mice, although the importance of T cell IL-23R expression in that study was not addressed (Nus et al., 2016) . Although T cells do not accumulate large amounts of cholesterol in the setting of hypercholesterolemia (whereas macrophages do), exposure to oxidized LDL and perturbations of T-cell-intrinsic cholesterol metabolism have profound effects on T cell functions and are implicated in T cell phenotypic modulation (Figure 2) . The liver has long been recognized as an important tissue site for the induction of peripheral T cell tolerance. Given the central role of the liver in handling dietary cholesterol and synthesis of lipoproteins, it is interesting to consider how hepatic T cells respond to changes in cholesterol homeostasis. Hypercholesterolemia in Western-diet-fed Ldlr À/À mice is reported to increase the numbers of intrahepatic Treg cells and expression of TGF-b, a cytokine that both drives Treg cell differentiation and is a principal immunosuppressive mediator secreted by Treg cells (Mailer et al., 2017) . Adoptive-transfer experiments have shown that these hepatic Treg cells home to atherosclerotic aortas. Furthermore, hypercholesterolemia induces either Th1 or Th17 cell differentiation of hepatic T cells depending on the presence or absence of LDL receptors. These data suggest that systemic changes in lipoprotein metabolism and dietary cholesterol could change the ratios of Treg and Th cell subsets generated in the liver, which would then change the ratios of the cells that enter plaques. The mechanisms by which hypercholesterolemia might influence Treg or Teff cell differentiation most likely involve effects on antigen-presenting DCs, which are found in atherosclerosisprone regions of arteries before lesion development and readily take up oxidized LDL (Paulson et al., 2010) . DCs maintain their antigen-presenting functions after becoming foam cells (Packard et al., 2008) and respond to cholesterol accumulation by increasing production of cytokines that drive differentiation of Th cell subsets (Westerterp et al., 2017) . However, there also appear to be direct effects of cholesterol on T cells. For example, T cells from mice deficient in the cholesterol transporter ABCG1 show increased proliferative responses to TCR stimulation, and T-cell-selective deletion of Abcg1 results in an increase in Treg cell differentiation from naive T cells (Armstrong et al., 2010) . In Ldlr À/À mice, T-cell-or Treg-cell-restricted ABCG1 deficiency results in more Treg cells, fewer Teff cells, and less atherosclerosis than in control mice (Cheng et al., 2016) . Interestingly, the ABCG1-deficient T cells accumulate more cholesterol in lysosomes than control T cells, which leads to inhibition of mTORmediated STAT5 signaling. These changes in energy metabolism favor Treg over Teff cell phenotypes, as discussed in the next section. T cell activation requires the assembly of antigen receptor and other signaling molecules in cholesterol-rich lipid rafts, which is a prerequisite for the formation of immune synapses with antigen-presenting cells. Therefore, alterations in cellular cholesterol might influence T cell activation because of changes in lipid-raft formation. This was shown to be the case for CD8 + Teff cells in mice in which cellular unesterified cholesterol was elevated by interventions that block the formation of cholesteryl ester . Cholesterol was increased in the plasma membrane of CD8 + T cells in these mice, and anti-tumor effector functions of the CD8 + T cells were increased. Thus, the net immunologic impact of changes in T cell cholesterol appears to vary depending on the intracellular compartment affected and on the T cell subset.
In two of the previously discussed studies, exposure of T cells to excess cholesterol, either through systemic hypercholesterolemia (Mailer et al., 2017) or through impairment of cholesterol efflux by ABCG1 deletion (Cheng et al., 2016) , was shown to favor Treg over Teff cell differentiation. This might seem surprising given the atheroprotective effect of Treg cells and the proatherogenic and pro-inflammatory effects of excess cholesterol and Teff cells. Perhaps the direct proinflammatory effects of hypercholesterolemia on macrophages and DCs overwhelm those on Treg cell development. Another possibility is that Treg cells generated in response to the cholesterol stimuli differentiate into Th1-like cells under hypercholesteremic conditions, as discussed earlier. In general, induction of regulatory mechanisms and inflammatory responses commonly occur together in the immune system, which must strike a fine balance between anti-microbial defense and protection of host tissues. This balance and the timing of the counteracting mechanism achieve defense against pathogens as well as subsequent resolution and return to homeostasis, thereby limiting collateral damage to healthy tissues and avoiding autoimmunity. In atherosclerosis, an emerging theme is that the balance is pathologically tipped toward the inflammatory side, and the regulatory mechanisms fail to move the scales to achieve resolution.
Energy Metabolism Affects Immune Cell Function in Atherosclerosis
An area of increasing interest is how changes in the metabolism of macrophages influence their phenotypes. Studies using cultured macrophages treated with either lipopolysaccharide (LPS) and IFN-g to model inflammatory macrophages or with IL-4 to model so-called alternatively activated macrophages have revealed certain preferences for metabolic pathways, but these associations are more complex than is generally portrayed (Van den Bossche et al., 2017) . For example, fatty acid oxidation (FAO) and oxidative phosphorylation are needed to support the phenotype of alternatively activated macrophages, but FAO is also involved in inflammasome activation in inflammatory macrophages. Conversely, whereas glycolytic metabolism has been associated with energy metabolism in inflammatory macrophages, glycolysis is also used by alternatively activated macrophages to fuel the tricarboxylic acid cycle for mitochondrial respiration. The role of metabolic shifts in determining the phenotype of macrophages in atherosclerotic lesions is not yet well characterized, but a few recent studies have shed light on this interesting topic. As one example, inflammatory macrophages were found to have increased expression of a particular microRNA, miR-33, and when miR-33 was silenced in cultured macrophages, the cells showed markers of alternative activation in association with increased expression of the genes encoding AMP kinase and FAO, elevated mitochondrial respiration, and decreased glycolysis (Ouimet et al., 2015) . In vivo, treatment of Western-diet-fed Ldlr À/À mice with anti-miR-33 led to a reduction in both plaque size and complexity and an altered lesionalmacrophage gene expression profile suggestive of alternative activation. Moreover, these changes were accompanied by an increase in athero-protective regulatory T cells in lesions, suggesting a link between immunometabolism in macrophages and innate-adaptive immunity crosstalk in the setting of atherosclerosis. As another example, investigators reported higher glucose uptake and glycolytic flux in monocytes and macrophages from patients with coronary artery disease (CAD) than in control subjects (Shirai et al., 2016) . In vitro experiments showed that this metabolic phenotype led to activation of a pathway involving mitochondrial oxidative stress (mitoOS) and pyruvate-kinase-M2-mediated STAT3 activation, which resulted in increased production of pro-atherogenic IL-6 and IL-1b. Other studies have suggested additional links between mitoOS and human CAD (Paneni et al., 2017) , and mitoOS in macrophages increases plaque progression, activates macrophage NF-kB, and promotes the formation of potentially atherogenic neutrophil extracellular traps in mouse models of atherosclerosis Wang et al., 2017) . In a follow-up to the glycolytic flux study above, the investigators found that the elevated glycolytic flux in macrophages from CAD subjects led to excess mitochondrial pyruvate, which drove BMP4-and IRF1-dependent expression of the T-cell-inhibitory protein PD-L1 (Watanabe et al., 2017) . The high PD-L1 expression on these macrophages was shown to block T cell activation, and the investigators correlated this with impaired anti-varicella zoster virus immunity in the CAD patients. Interestingly, one mechanism of the de-activating effect of PD-1 on T cell activation could involve PD-1-mediated suppression of glycolysis in the T cells themselves, as has been shown recently for CD8 + T cells (Bengsch et al., 2016) . As with the miR-33 study mentioned above, glycolysis-induced PD-L1 in macrophages demonstrates how macrophage metabolic changes can be linked to regulation of T cells, except in this case glycolysis-driven macrophage inflammation downregulates T cell activation. This T-cell-suppressive process represents another example of a counter-regulatory pathway that is induced concurrently with the induction of pro-inflammatory pathways. PD-L1 induction does not prevent lesion development but is likely to provide a beneficial effect by limiting lesion growth and inflammation. Consistent with this concept is the finding that deficiency of PD-1 or PD-L1 in Ldlr À/À mice fed a high-fat diet enhances lesion development and plaque inflammation in comparison with the baseline lesion development that occurs despite the presence of PD-L1 in wild-type mice (Lichtman, 2012) . Similarly, a recent study showed that hypercholesterolemia induces PD-L1 expression on marginal zone B cells, which inhibits pro-atherogenic T follicular helper cell responses (Nus et al., 2017) . Another environmental factor that can affect macrophage metabolism in advanced atherosclerotic lesions is hypoxia. Hypoxic conditions exist in atherosclerotic plaques, leading to increased expression of hypoxia-inducible factor-1a (HIF-1a) (Marsch et al., 2013) . A recent study found that hypoxia markedly increased glycolysis in cultured macrophages exposed to inflammatory cytokines or oxidized LDL. This effect was associated with a HIF-1a-dependent increase in mRNAs encoding glycolysis-promoting enzymes, notably hexokinase II (Hk2) and 6-phosphofructo-2-kinase (Pfkfb3), and with an amplified production of inflammatory cytokines (Tawakol et al., 2015) . In Western-diet-fed Apoe À/À mice, inhibition or silencing of either Pfkfb3 or Hif1a attenuated lesional glycolysis and decreased the expression of inflammatory cytokines, albeit the net effect on lesion development was not reported. Although this study suggests that HIF-1a can be pro-inflammatory, HIF-1a in CD11c-expressing cells might have the opposite effect, given that CD11c-cre-mediated deletion of Hif1a in Ldlr À/À mice results in increased lesion development and more T cells in the plaques (Chaudhari et al., 2015) . The HIF1a-deficient APCs express less STAT3 and more IL-12, which is associated with increased Th1 cell differentiation, and lentivirusinduced overexpression of STAT3 in bone marrow cells reverses the effects of the Hif1a deletion. Lyz2-cre-mediated Hif1a deletion does not have the same effects on lesion development or T cells, indicating that HIF-1a deficiency in DCs is the likely cause of the pro-atherogenic phenotype. As in macrophages, changes in energy metabolism in T cells are also linked to functional phenotypes, and these metabolic-functional T cell states might synergize with proatherogenic or resolving functions of monocytes and macrophages systematically or within atherosclerotic lesions. In this regard, two important differences between T cells and macrophages are (1) the requirement of rapid proliferative expansion for generating Teff cells from naive or resting memory cells and (2) the greater diversity of specialized functional phenotypes of T cells. These features are reflected in many different metabolic states in T cells depending on the stage of the T cell response and the functional subset of the T cell (MacIver et al., 2013) . Resting naive T cells use the tricarboxylic acid (TCA) cycle to oxidize glucose-derived pyruvate, lipids, and amino acids and efficiently generate ATP. Antigen-induced clonal proliferation requires increases in aerobic glycolysis and lipid synthesis and a decrease in lipid oxidation. The resting-memory T cells that survive at the end of a T cell response go back to efficient energy generation but mainly by lipid oxidation. Furthermore, there are distinct metabolic phenotypes in different T cell subsets. Effector Th cells, including Th1, Th2, and Th17 cells, require mTOR and aerobic glycolysis for differentiation. However, whereas Th1 and Th17 cells depend on active mTORC1 activity, Th2 cells depend on mTORC2. In contrast, Treg cell generation is regulated by AMP-activated protein kinase (AMPK) and relies on lipid oxidation through the TCA cycle. Given the opposing roles of Th effector cells and Treg cells on atherosclerosis and the possible different influences of Th cell subsets, the impact of atherosclerosis-associated systemic modulators of cellular metabolism and the local metabolic environment of the plaque are likely to affect how T cells contribute to lesion progression.
Of relevance to how the local plaque environment might influence T cell metabolism and function, a recently published study has shown that effector-memory T (Tem) cells, the functional phenotype of most T cells found in plaques, respond to hypoxia by increased HIF-1a expression, which in turn increases proliferation, viability, and cytotoxicity . This is not the case for naive or central-memory T cells and is in contrast to the finding of increased T cell inflammation in plaques in Western-diet-fed Ldlr À/À mice with DC-restricted deletion of Hif1a (Chaudhari et al., 2015) . GAPDH was shown to block HIF-1a translation, and the increased glycolytic activity in Tem cells reduced GAPDH, resulting in elevated HIF-1a expression.
A recent study has shown that FoxP3, the defining Treg cell transcription factor, is responsible for maintaining a metabolic state in which glycolysis is repressed and oxidative phosphorylation and nicotinamide adenine dinucleotide oxidation are increased. This state allows Treg cells to function in low-glucose, lactaterich environments that impair Teff cell function and proliferation (Angelin et al., 2017) . The likely influence of the plaque environment on T cell metabolic states and function has not yet been experimentally established.
Aging Affects Immune Cell Function in Atherosclerosis
Aging is a major risk factor for atherosclerotic disease (Lakatta and Levy, 2003) . One of the consequences of aging is an accumulation of somatic mutations in hematopoietic stem cells (HSCs) which has been linked to increased clonal hematopoiesis and cardiovascular disease (Jaiswal et al., 2014; Jaiswal et al., 2017) (Figure 2) . One of the genes affected by age-related HSC somatic mutations is TET2, which encodes an epigenetic modifier enzyme that can also repress inflammatory gene expression in human and mouse macrophages and DCs by recruiting histone deacetylases (HDACs) . The genes repressed by TET2 include IL6 and several chemokine-encoding genes. In Western-diet-fed Ldlr À/À mice, partial bone marrow reconstitution with TET2-deficient hematopoietic cells leads to clonal expansion of these cells, with a myeloid bias, and increased atherosclerosis with an enrichment of Tet2 À/À lesional macrophages (Fuster et al., 2017; Jaiswal et al., 2017) . The proatherogenic effect of TET2 deficiency in mice has been ascribed to inflammasome activation (Fuster et al., 2017) . Mechanistic studies have shown that the ability of TET2 to suppress the inflammasome does not depend on its canonical activity of oxidizing 5-methylcytosine but rather on HDAC-mediated suppression of Il1b and inflammasome component genes. However, because the in vivo causation study in this report used a chemical inhibitor of the inflammasome, the relative contribution of the inflammasome to the pro-atherogenic effect of TET2 deficiency will need to be confirmed by genetic approaches. Other areas for future studies include relevance to human lesions in subjects with somatic TET2 mutations and the atherosclerosis-related impact of somatic mutations on DC function and T cell responses. Importantly, one of the studies cited above showed strong associations between CAD and age-related somatic mutations in a number of genes associated with clonal hematopoiesis of indeterminate potential, including TET2 but also DNMT3A, ASXL1, and JAK2 (Jaiswal et al., 2017) . These findings have potentially important implications related to risk stratification and possibly new and/or more tailored treatment strategies. Aging is also associated with the accumulation of so-called senescent cells, which, in chronic diseases of aging, can contribute to a maladaptive inflammatory response via secretion of inflammation-inducing factors. Advanced atherosclerotic lesions contain cells with markers of senescence, including senescence-associated b-galactosidase, p16 Ink4a , p53, p21, and shortened telomeres (Minamino and Komuro, 2007) . Although indirectcausation studies in mice originally suggested a pro-atherogenic role of senescent lesional cells, genetic association studies in mice and humans have called into question this conclusion (Schierwagen et al., 2017) . However, a more definitive causation study was recently conducted with Western-diet-fed Ldlr À/À mice in which lesional macrophages, VSMCs, and endothelial cells expressing p16
Ink had been genetically eliminated (Childs et al., 2016) . Compared with the control cohort, the engineered mice had smaller lesion size and decreased lesion complexity without changes in pro-atherogenic systemic factors. In particular, the mice had a marked decrease in cholesteryl-ester-laden macrophages (foam cells) with markers of senescence, and this was accompanied by decreases in inflammatory cytokines and matrix metalloproteinases and an increase in fibrous-cap thickness. In addition to suggesting a role of senescent cells in 
Resolution of Inflammation Is Impaired in Atherosclerosis and Contributes to Plaque Progression
In normal physiology, the inflammatory response is directly linked to a resolution phase that repairs collateral damage and restores tissue homeostasis (Serhan et al., 2007; Nathan and Ding, 2010) . Resolution is mediated by (1) inflammation-induced endogenous lipids, called specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins (Serhan, 2010) ; and (2) proteins such as IL-10, TGFb, and annexin A1 (Perretti and D'Acquisto, 2009) . By activating specific cell-surface receptors, these mediators block inflammatory cell influx and promote their egress; clear pathogens, cellular debris, inflammatory cytokines, and apoptotic cells (efferocytosis); and repair tissue damage (Serhan, 2010; Perretti and D'Acquisto, 2009 ). In chronic diseases in which the inciting pathologic process is persistent, resolution becomes defective as a result of impaired synthesis or increased degradation of resolution mediators and as a result of decreased resolution mediator action on cells that effect the repair process (Serhan, 2010) . This defect leads to an amplification cycle of continual tissue injury and DAMP-mediated inflammation and, in the case of atherosclerosis, plays a key role in the clinical progression of plaques (Merched et al., 2008; Tabas, 2010; Viola and Soehnlein, 2015) . In this context, several key features of clinically dangerous advanced plaques, including defective efferocytosis, plaque necrosis, DAMP-mediated inflammation, thinning of the fibrous cap, and oxidative stress, are characteristic of impaired resolution. Moreover, the ratio of resolving to inflammatory lipid mediators is markedly lower in advanced murine and human plaques than in earlier lesions Viola et al., 2016) . The therapeutic potential of enhancing resolution in chronic diseases such as atherosclerosis could be substantial in that SPMs, unlike anti-inflammatory drugs, suppress inflammation and promote tissue repair in a manner that is less likely to compromise host defense than drugs directly targeting the inflammatory response (Serhan et al., 2007; Tabas and Glass, 2013) . A lesional-macrophage resolution process that has received particular attention in the field of atherosclerosis is efferocytosis (Tabas, 2005; Schrijvers et al., 2007; Linton et al., 2016; Van Vré et al., 2012) . Efferocytosis is mediated through phagocyte receptors, apoptotic cell ligands, bridging proteins, and chemoattractants. It is normally a high-capacity and efficient process, but when it goes awry, tissue necrosis and subsequent DAMP-mediated inflammation occur (Henson et al., 2001; Camenisch et al., 1999) . A critically important example of this principle is advanced atherosclerosis (Geng and Libby, 1995; Schrijvers et al., 2005; Otsuka et al., 2015) . Clinically dangerous human coronary plaques show evidence of defective efferocytosis, i.e., abundant uncleared dead cells, and this defect correlates with two key features of these plaques-necrosis and inflammation. Causation is suggested by studies using genetically altered mice. For example, when efferocytosis is compromised through gene targeting of effector molecules, there is an increase in uncleared apoptotic cells, inflammation, and plaque necrosis (Yancey et al., 2010; Tao et al., 2015; Cai et al., 2017) .
The unresolved mechanisms of defective efferocytosis in advanced plaques represent a major gap in this field. In theory, defects could arise in processes that occur during apoptosis and normally ensure proper recognition or uptake by lesional phagocytes, or they could arise in the phagocytes themselves. Providing an example of the former scenario, a recent study has presented evidence that lesional apoptotic macrophages, under the influence of inflammatory signaling, continue to express a ''don't-eat-me'' cell-surface protein-CD47-that is normally extinguished when cells die (Kojima et al., 2016) . By interacting with a molecule on phagocytes called SIRPa, CD47 suppresses cell internalization by the phagocyte, and thus its persistence on lesional dead cells contributes to defective efferocytosis. With regard to phagocyte defects, there is evidence that lesional hypoxia might lead to decreased expression of a key efferocytosis receptor (called MerTK) on macrophages and thereby compromise the ability of lesional macrophages to recognize apoptotic cells (Marsch et al., 2014) . Another mechanism of defective efferocytosis related to MerTK is ADAM17-mediated MerTK cleavage. There is evidence that MerTK cleavage occurs in advanced, necrotic human coronary plaques (Garbin et al., 2013; Cai et al., 2017) , and compared with mice expressing wild-type MerTK, Western-diet-fed Ldlr À/À mice expressing an engineered non-cleavable mutant of MerTK show improved lesional efferocytosis and decreased plaque necrosis (Cai et al., 2017) . Interestingly, these lesions also have additional signs of improved resolution, such as thicker fibrous caps, and they have an increase in the ratio of resolving to inflammatory lipid mediators, which is consistent with a previous study showing that holo-MerTK deficiency decreases plaque inflammation (Ait-Oufella et al., 2008) . Mechanistic studies have revealed that a MerTK signaling pathway in macrophages promotes the biosynthesis of resolving lipid mediators at the expense of inflammatory lipid mediators (Cai et al., 2016) . These studies suggest an amplification loop in which resolving mediators promote efferocytosis and then efferocytosis promotes the synthesis of resolving mediators. Thus, therapeutic strategies that could convert the pro-atherogenic cycle of defective efferocytosis, i.e., impaired efferocytosis exacerbating DAMP-mediated inflammation, to this beneficial feedback cycle might be particularly effective at preventing advanced plaque progression. Considering the intricate relationships between innate and adaptive effectors in chronic inflammatory processes, the macrophage contributions to defective resolution in plaques are likely to enhance and be aggravated by Teff cell responses. Conversely, pro-resolving interventions would be expected to engage regulatory T cells. There is evidence that Treg cells increase during the resolution phase of innate inflammatory processes in mouse models and help shape the resolution process. For example, after bacterial and worm infections in fate-mapping reporter mice, Th17 cells were shown to transdifferentiate into FoxP3 Treg cells as inflammation resolved (Gagliani et al., 2015) . In a lung model of self-limited allergic inflammation, the SPM maresin 1 was shown to induce Treg cells, which then inhibited type 2 innate lymphoid cells. A recent in vitro study showed that SPMs can block differentiation of naive human T cells to Th1 and Th17 cell effectors, block inflammatory production of cytokines (including IFN-g) (Cai et al., 2017) . These initial reports set the stage for future studies that will further define T cell contributions to the resolution state and determine how these contributions can be leveraged by pro-resolving therapeutics in atherosclerosis.
Summary and Therapeutic Considerations
Our understanding of the ways in which innate and adaptive immunity influence atherosclerotic disease has continued to evolve along with emerging areas in immunology research. In this review, we have emphasized selected themes, including the dynamics and heterogeneity of macrophage and T cell phenotypes, the impact of cellular and systemic metabolic states on immune cell phenotypes, and the ways in which macrophage and T cell functions affect the balance between progression and resolution of plaque inflammation. These emerging areas of investigation have raised new questions, but they have also validated current efforts at modifying existing targeted therapeutic approaches and developing new strategies. Viewing the pathogenesis of atherosclerosis as an immunological reaction to retained and modified apoB LPs in the arterial wall emphasizes the fundamental importance and success of plasma apoB-LP-lowering therapies, including statins, ezetimibe, and now PCSK9 inhibitors (Boré n and Williams, 2016) . By lowering the concentration of apoB LPs in the blood, which then lowers their infiltration into developing lesions, these therapies decrease the burden of DAMPs and antigens that drive innate and adaptive immune responses in the artery. Moreover, as discussed above, hypercholesterolemia can promote atherogenic activation of circulating immune cells and their precursors even before they enter developing lesions. If cholesterol-rich apoB LPs were lowered below a certain threshold concentration, this alone would most likely halt plaque progression and induce regression. However, this potential has not been met as a result of a variety of issues, one example of which is the counteracting effects of obesity-induced insulin resistance. Insulin resistance is a potent risk factor for atherosclerotic heart disease because of its links to dyslipidemia and inflammation and because of the effects of high insulin and glucose on atherosclerotic lesional cells (Razani et al., 2008; Bornfeldt and Tabas, 2011) . Indeed, largely as a result of the massive increase in the prevalence of obesity and insulin resistance, atherosclerotic vascular disease remains the leading cause of death in the industrialized world, and its prevalence is expected to rise over the next 20 years (Go et al., 2013; Behn and Ur, 2006 ; American Heart Association and American Stroke Association, 2017). In this regard, a topic of great interest is how insulin resistance might affect the immune processes discussed in this review and thereby exacerbate atherosclerosis (Han et al., 2006; Kanter et al., 2012; Nagareddy et al., 2013; Willecke et al., 2015) . Moreover, as the number of patients being treated with PCSK9 inhibitors increases, we might have an opportunity to learn how lowering cholesterol below the concentrations achieved with statins alters immune parameters of atherosclerosis, even in the face of the widespread increase in obesity (Dullaart, 2017; Boré n and Williams, 2016) . Cytokine-targeted therapies, such as TNF or IL-17 antagonists, have transformed the treatment of autoimmune diseases, including rheumatoid arthritis and psoriasis. These diseases carry increased cardiovascular risk, but whether the anti-cytokine therapies used to reduce the autoimmune pathology directly affect plaque inflammation and progression is not clear. The recently completed Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial of an anti-IL1b-blocking antibody (canakinumab) in subjects with a history of MI and an elevated serum concentration of high-sensitivity C-reactive protein (hsCRP) is the first clinical study of the effectiveness of an anti-cytokine therapy given explicitly for cardiovascular disease (Ridker et al., 2017) . Compared with the placebo, treatment of over 10,000 patients with canakinumab was shown to reduce the risk of secondary nonfatal MI, nonfatal stroke, and/or cardiovascular death by 15%. Canakinumab treatment significantly lowered serum hsCRP and IL-6 concentrations but had no effect on lipids, suggesting that the reduction of cardiovascular risk was directly related to anti-inflammatory effects. The currently active Cardiovascular Inflammation Reduction Trial will determine whether MI or stroke in a highrisk population can be decreased by a regimen of low-dose methotrexate, which is an immunosuppressant that targets cytokine-producing immune cells and has long been used to treat rheumatoid arthritis (Ridker et al., 2012) .
A concern for strategies that attack immune activation for a chronic disease process such as atherosclerosis is compromised host defense. Indeed, the risk of fatal infection was significantly increased in the canakinumab-treated group in the CANTOS trial (Ridker et al., 2017) . The realization that physiologic mechanisms underlying the resolution of inflammation are impaired in the human plaque environment and that pro-resolution therapy might not compromise host defense as much as anti-inflammatory therapy has led to active work in developing therapies based on the delivery of pro-resolution mediators into lesions (Fredman et al., 2015; Hasturk et al., 2015; Viola et al., 2016; Petri et al., 2017) . Another challenge to treating chronic autoimmune diseases is the accumulation of autoreactive tissue-resident memory lymphocytes, whose pathogenic phenotypes are stabilized by epigenetic modifications of various gene loci (Phan et al., 2017) . There is also evidence that metabolic conditions can induce epigenetic changes in macrophages and thus lead to a form of innate immune memory (''trained immunity'') Phan et al., 2017 ) that might promote lesion progression (Bekkering et al., 2016) . In this regard, pre-clinical studies have provided support for the principal that targeting physiologic epigenetic modifiers, e.g., with inhibitors of bromodomain and extra-terminal motif (BET) proteins, can inhibit inflammatory gene expression and reduce atherosclerosis (Brown et al., 2014; Jahagirdar et al., 2014) . Many pre-clinical studies have validated the concept of treating atherosclerosis with therapeutic vaccinations that tolerize against antigens that drive proatherogenic T cell responses. Recent progress in this area has included identification of apoB100 peptide epitopes that bind mouse or human class II major histocompatibility complex (MHC) glycoproteins and the demonstration that vaccination of mice expressing MHC molecules that can bind the peptide reduces lesion formation Kimura et al., 2017) . Evidence suggests that the mechanism of protection is induction of Treg cells (Kimura et al., 2017) or antibodies that block LDL activation of macrophages . Immunity Review Careful assessment of the efficacy and adverse effects of these new therapies, as well as future ones that will undoubtedly be conceived as we learn more about the immune mechanisms that drive atherosclerosis, represents an important ongoing effort to complement apoB-LP-lowering therapy for the prevention and treatment of atherothrombotic vascular disease.
